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ACUTE CONSTIPATION IN CHILDREN RECEIVING CHEMOTHERAPY FOR CANCER.   
J. Hale Season, Farzana D. Pashankar, Joseph McNamara, and Dinesh S. Pashankar.  
Sections of Pediatric Gastroenterology and Pediatric Hematology-Oncology, 
Department of Pediatrics, Yale University, School of Medicine, New Haven, CT.   
We hypothesized that the prevalence of constipation amongst children on 
chemotherapy would be high, and that certain pharmacologic interventions commonly 
used in this population (especially vinca alkaloids, narcotic analgesics, and ondansetron) 
would be associated with constipation.  We also hypothesized that constipation would 
be perceived as an important problem with a significant impact on lifestyle.  We 
prospectively studied 61 children receiving chemotherapy for cancer by administering 
questionnaires to patients and their parents. We obtained demographics, bowel 
movement history, interventions for constipation, chemotherapy agents, other 
medications, perception of constipation as a problem, and impact on lifestyle.  35 of 61 
(57% ± 12%) children were found to meet NASPGHAN criteria for constipation during 
chemotherapy, while 46 of 61 (77% ± 11%) were found to have signs and symptoms 
suggestive of constipation and 42 of 61 (69% ± 12%) required the use of laxatives while on 
chemotherapy.  Among children with NASPGHAN criteria constipation, 15 of 35 (43% ± 
16%) perceived it as a major/significant problem and 8 of 35 (23% ± 14%) noted a 
major/significant impact on lifestyle.  We concluded that criteria for acute constipation 
were found in 57% of children receiving chemotherapy for cancer, though less stringent 
criteria suggest a prevalence of up to 77%.  Even though this study lacked sufficient 
power for most associations, combined use of vincristine and opiates was associated 
with constipation (p<0.03).  Constipation was found to have a high prevalence in 
children on chemotherapy, and it is perceived as a significant problem by patients and 
their parents with an adverse effect on lifestyle. 
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Introduction and Background 
Constipation is a common problem in the pediatric population in 
general, however it is particularly common in children receiving 
chemotherapy for cancer (1).  This common chemotherapy-associated 
adverse effect is well known to pediatric oncologists; a 2005 survey of 12 
pediatric oncology units (54% response rate) in the United Kingdom 
demonstrated that 100% perceived constipation as a problem within their 
patient group, an observation which has been echoed by pediatric 
oncologists at Yale-New Haven Hospital and at Children’s Hospital in 
Leeds, United Kingdom (1-3).  Despite this high awareness, there is no 
published research focused on constipation in the pediatric oncology 
population (other than that which was published based on this thesis) (2).  
A 2008 systematic review of treatments for constipation in children and 
young adults undergoing chemotherapy reviewed 1336 abstracts and 
failed to find even a single article which was suitable for inclusion, as none 
included pediatric patients (3).  As far as we are aware, no prior study had 
yet tried to assess either the extent or the impact of constipation in this 
population, both of which might currently be underappreciated by 
clinicians.   
We therefore planned a prospective study to evaluate the 
prevalence of constipation in children undergoing chemotherapy in New 
Haven county using an in-person interview and questionnaire.  We also 
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tried to assess perceptions of patients and family members about the 
degree to which constipation was a problem and its impact on quality of 
life, while also investigating likely risk factors for constipation and 
treatment strategies used to treat bouts of constipation.   For the purposes 
of this study, we defined constipation according to the North American 
Society for Pediatric Gastroenterology, Hepatology, and Nutrition 
(NASPGHAN) criteria because, which defines constipation as delay or 
difficulty in defecation for 2 or more weeks (45). 
Constipation, in the general pediatric population, has a significant 
healthcare impact.  It accounts for 3-10% of visits to general pediatric 
practitioners and up to 25% of referrals to pediatric gastroenterologists 
worldwide (4-6).  Studies on the worldwide prevalence of functional 
constipation have found that the rate varies from 0.7% to 29.6% and is 
common in all pediatric age ranges, from infants to young adults (7,8).  
Given this high prevalence, constipation is associated with high 
healthcare expenditures.  Costs per individual are also significant, 
especially as constipated children have been shown to have more visits 
to outpatient clinics and emergency departments and more inpatient 
admissions than matched controls (9).  A 2006 prospective study 
calculated the mean annual expenditure for treatment of chronic 
constipation to be $7,522 per patient, with an average diagnostic study 
cost of nearly $3,000 per patient (10).  While a 1993 British study found that 
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GBP£43 million is spent annually on prescription laxatives, and an analysis 
of three United States surveys estimated the total health-related cost of 
adult constipation to be US$235 million in 2001, pediatric constipation in 
the United States has been estimated using the Medical Expenditure 
Panel Survey database to cost US$3.9 billion per year (11-13). 
Stooling frequency and bowel habits reflect a pronounced 
interindividual variation which makes defining “normal” a frustrating task, 
however the bounds of normal habits can be loosely defined with regards 
to age. A 1989 study used diary recordings to characterize the bowel 
habits of 662 children in Italy.  Starting at age three, most children will 
have between three stools per week to three stools per day, and by age 5 
to age 8 most children will have settled into a more consistent medium-
sized bowel movement, either daily or every other day, without straining or 
exhibiting withholding behavior (14,15).   
Dealing with constipation, however, presents a challenge as the 
term has many different meanings to different people, from children, to 
parents, to physicians and researchers (16).  To patients it can mean the 
need for excessive straining, hard stools, infrequent stools, infrequent 
defecation, the inability to defecate when desired, abdominal pain or 
discomfort, or the sensation of an incompletely evacuated bowel (17).  
Given the nonspecific nature of these symptoms, many of them will be 
experienced in the absence of any pathology; indeed, a 2011 study 
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showed that 20% of 10 to 16-year-olds have at least 1 clinical feature of 
constipation (18).  As a result, physicians have attempted several times to 
define more specific criteria for the constipation.  Constipation has been 
traditionally defined as less than 3 bowel movements per week, however 
patient self-reports of bowel frequency have been shown to be 
inaccurate and poorly correlated with other signs and symptoms of 
constipation (19).  In 1999, gastroenterology clinicians put forward the 
Rome II criteria for functional constipation based largely on expert 
opinion, criteria which were soon found to be too restrictive and thus 
insensitive for constipation (16).  These standards were then revised and 
broadened between 2004 and 2006, and they define constipation as 
having at least two of the following at least weekly for at least 2 months 
(without evidence of an organic disease which could be causing them): 2 
or fewer bowel movements in the toilet per week, episodes of fecal 
incontinence in children > 4 years of age, history of retentive posturing or 
excessive volitional stool retention, history of painful or hard bowel 
movements,  history of large diameter stools which may obstruct the toilet, 
or the presence of a large fecal mass in the abdomen or rectum (20).  
Infants can also be diagnosed with a similar functional disorder, infant 
dyschezia, if an otherwise healthy infant less than 6 months of age 
endures 10 minutes of straining and crying before passing soft stools.  The 
changes in the Rome III criteria resulted in a 42% jump in children being 
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diagnosed with functional constipation (21).  Alternatively, as the Rome III 
criteria still sacrifice sensitivity for specificity by having more stringent 
criteria and longer duration requirements, the North American Society for 
Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) offer 
an alternate and less restrictive definition of constipation as delay or 
difficulty in defecation for 2 or more weeks (45). 
For many children, constipation is triggered by the occurrence of 
painful bowel movements, often the result of toilet training, delaying 
defecation, changes in routine, changes in diet, stressful events, or illness 
(22).  Peak incidence occurs at about the time of toilet training (8).  As 
feces are retained within the colon, more water is reabsorbed over time, 
and stools become harder and more difficult to pass, and defecation 
becomes more painful.  This can cause the accumulation of hard stool in 
the rectal vault and the onset of fecal impaction (22).  It can also lead to 
overflow fecal incontinence or loss of the normal urge to defecate (16).  
Some children with chronic constipation have also been found to have 
reduced rectal sensation, increased rectal wall compliance, or both.  This 
can manifest itself as megarectum, though it is unknown whether these 
sensorimotor dysfunctions are primary or secondary to constipation 
(16,23). 
 Suggested risk factors for constipation include genetics (a family 
history of constipation), low consumption of fiber (which functions as an 
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osmotic laxative and a mechanical stimulator of colonic motility), low 
levels of physical activity, obesity, living in a high-population-density 
community and low parent education levels (7,24).  Constipation has also 
been associated with behavioral problems, though cause and effect can 
be difficult to discern as constipation can be both a source and a 
manifestation of behavioral problems (25).  Inan et al has shown that 
physical trauma, psychological trauma, abnormal oral habits (considered 
a proxy for emotional stress), and personal health problems are also all 
significantly associated with constipation (26).  Stress-mediated effects 
likely act through decreased parasympathetic stimulation of the enteric 
nervous system, resulting in decreased motility, decreased secretions, and 
constipation.  Many of these factors are very relevant to the pediatric 
patients on chemotherapy, who are at particular risk for decreased oral 
intake, low activity levels, severe health-related stress, and trauma from 
the side effects of chemotherapy.  
The pathophysiology of pediatric constipation is still not completely 
understood, though it is certainly multifactorial.  In some patients, the 
constipation is secondary to a known organic disorder or is medication 
induced.  Possible organic causes include intestinal causes (Hirschprung 
disease, anorectal malformations, neuronal intestinal dysplasia), 
neuropathic conditions (spinal cord abnormalities, spinal cord trauma, 
neurofibromatosis, static encephalopathy, tethered cord), 
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metabolic/endocrine disorders (hypothyroidism, diabetes mellitus, 
hypercalcemia, hypokalemia, vitamin D intoxication), drug induced 
(opiates, drugs with anticholinergic effects, antidepressants, vinca alkaloid 
neuropathy), anorexia nervosa, sexual abuse, scleroderma, cystic fibrosis 
or a dietary protein allergy.  Children on chemotherapy tend to have 
acute secondary or iatrogenic constipation, often with multiple possible 
organic causes, however >90% of children presenting with constipation 
have no obvious organic cause, and a diagnosis of functional 
constipation is made (16).  As a result, the available and widely used 
Rome III and NASPGHAN definitions used to diagnose constipation were 
developed with functional constipation in mind, and no universally 
accepted criteria exist for acute secondary or iatrogenic constipation.  
For the purposes of this thesis, I will evaluate constipation focusing on the 
less restrictive NASPGHAN definition with its shorter time requirements (2 
weeks), which is more applicable to acute constipation than the 2 month 
requirement stemming from the chronic and functional orientation of the 
Rome III criteria.  I will also show results using the Rome III criteria, removing 
the 2 month requirement, side-by-side with the NASPGHAN criteria as well 
as other signs and symptoms suggestive of constipation. 
 While there are no original studies on the prevalence or treatment 
of constipation in the pediatric oncology population, many studies have 
been done regarding adults with cancer.  There is much to be learned 
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from the adult literature which is likely applicable to the pediatric 
population.  It is widely documented that over 50% of adult patients on 
chemotherapy experience constipation as a result of their treatment (27-
30).  These adverse gastrointestinal effects have been shown to be one of 
the most distressing symptoms that result from cancer and its treatment 
with regards to self-esteem, daily living, and social acceptance, 
emphasizing the importance of addressing this often underestimated 
complication (31).  Effects of this condition are, however, more than just 
psychological.  Constipation can cause pain, anorexia, nausea, vomiting, 
hemorrhoids, anal fissures and perianal abscesses (32).  Constipation can 
be particularly dangerous or even fatal in this patient group if fissures or 
abscesses develop in a neutropenic patient, risking systemic infection.  In 
the adult population, constipation is seen as a failure of prevention, and 
its continued occurrence and role in hospital admissions is seen as 
unacceptable.  It has been suggested that cancer-related constipation 
does not get the attention it deserves (27). 
 In the adult population, various chemotherapy agents have 
already been strongly associated with constipation.  Patients receiving 
vinca alkaloids (vincristine/vinblastine) have been shown to experience 
constipation at a rate of up to 35%, while for carboplatin one study 
demonstrated a constipation rate of 70% (27,33).  Constipation has also 
been strongly linked to opiates and the antiemetic ondansetron (34-36).  
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The constipating effects of ondansetron are, in particular, most often 
overlooked as they are less well known to be a side effect.  Furthermore, 
nurses may be more focused on monitoring antiemetic effects than side 
effects, and constipation may be seen as a worthy trade-off to relieve 
nausea (27,37). 
 Importantly, some of the adult literature emphasizes the importance 
of prophylactic treatment with laxatives before the onset of constipation.  
As Smith put it in the opening of his review on constipation in the oncology 
patient, “A need to treat constipation is often due to a failure to prevent 
it” (27).  In one study which tracked ten newly-diagnosed osteosarcoma 
patients entering treatment, six were admitted for reasons related to 
constipation, and four developed systemic infections from an anal fissure 
or abscess (27).  Authors have noted that intervention is often delayed 
until a significant problem sets in, and that this is likely due to a lack of 
consensus on treatment protocols (27,38).  Significantly, protocols for 
prophylaxis do exist for morphine, codeine, vinca alkaloids, and 
ondansetron (27).  The need for similar prophylactic protocols has been 
proposed for children on chemotherapy as well (1). 
 While no data exists in the pediatric oncology literature regarding 
constipation, many studies have been done regarding prophylaxis and 
treatment of nausea and vomiting for children (2).  One such study was a 
double-blind, crossover, randomized study evaluating the safety and 
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efficacy of two doses of granisetron for the prophylactic prevention of 
nausea when receiving emetogenic doses of carboplatin (39).  As Berrak 
notes in that study, “Without effective prophylaxis, severe and protracted 
nausea and vomiting may result in dehydration, electrolyte imbalance, 
malnutrition, aspiration pneumonia, and increased hospitalization rates 
(40). Furthermore, these symptoms may be so distressing that the patients’ 
quality of life can be affected, leading to the discontinuation of life-saving 
medications (41). Therefore, effective and well-tolerated antiemetic 
therapy is vital for patients receiving intensive chemotherapy.”  A very 
similar argument could be made for constipation. 
 As we could find no data on constipation in children receiving 
chemotherapy for cancer, we designed a prospective survey study to 
establish the prevalence of constipation in this population.  We also 
studied the prevalence of suspected risk factors for constipation in this 
group, the association of certain chemotherapy agents and drugs to 
constipation, and the degree to which constipation was perceived as a 
problem with an impact on the lives of patients and their families.  We also 
looked at laxative use patterns and their effectiveness.  The validity and 
clinical utility of a brief bowel habit questionnaire to detect the presence 
of medically significant constipation (MSC) has been established by Wald 
et al in 2011, with the questionnaire having a sensitivity of 59.6% (95% 
confidence interval [CI] of 46.7%-71.4%) and a specificity of 82.9% (95% CI 
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77.0%-87.1%).  The questionnaire was classified as positive if a child scored 
2 or higher, with 1 point each for <3 bowel movements per week, at least 
one stool accident in the previous two weeks, straining at stool >25% of 
the time, passing “very large stools” >25% of the time, avoidance >25% of 
the time, or discomfort with defecation >25% of the time.  MSC was 
established prospectively with a detailed diary (42).  It should be noted 
that this study was focusing on functional constipation, not acute 
iatrogenic constipation and thus involved frequency of symptoms.  
Parent-reported answers to questions in surveys to measure for the 
opinions of patients when they are either too young or too sick to give a 
self-report (43) 
 
Purpose, Hypothesis, and Specific Aims 
 Consideration of palliative care in the treatment of cancer in 
children is widely recognized as an essential cornerstone of appropriate 
management in caring for these patients.  In the pediatric literature, it is 
widely accepted that addressing side effects of cancer treatment is 
essential to maximizing acceptance of, and compliance with, life-saving 
treatment regimens (39).  Severe constipation may also cause life-
threatening complications which require a reduction in the intensity of 
anticancer treatment (44).  Of equal importance, constipation has a large 
and likely underestimated effect on quality of life in children on 
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chemotherapy (1,3).  Limited studies of treatment policies of oncology 
practices have shown that protocols for prophylaxis or standard treatment 
of constipation while administering chemotherapy are uncommon, while 
standardization is absent (1,27).  A recent systematic review of treatments 
for constipation in children and young adults undergoing cancer 
treatment failed to find even a single study eligible for inclusion.  No study 
to our knowledge has even attempted to quantify the problem, 
demonstrating a need to address this widely-known but possibly under-
addressed side effect of cancer treatment.  We thus designed a 
prospective study to establish the prevalence of constipation in the 
pediatric oncology population receiving chemotherapy, which may 
suggest a need for more aggressive and possibly prophylactic 
management.  We also aimed to demonstrate the association of certain 
chemotherapy agents and drugs to constipation, and the degree to 
which constipation was perceived as a problem with an impact on the 
lives of patients and their families.  While not a principle aim of this study, 
we also looked at laxative use patterns with a goal of characterizing their 
use and commenting on their effectiveness and the consistency of 
regimens.  This would have the potential to provide the basis to suggest 
the need for future work to evaluate strategies for the management of 
constipation.    
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 We hypothesized that the prevalence of constipation amongst 
children on chemotherapy would be high, and that certain 
pharmacologic interventions commonly used in this population (especially 
vinca alkaloids, narcotic analgesics, and ondansetron) would be 
associated with constipation.  We also hypothesized that constipation 
would be perceived as an important problem with a significant impact on 
lifestyle. 
 The specific aims of this study were to 1) determine the prevalence 
of constipation in children on chemotherapy, 2) assess the association of 
factors such as chemotherapy type and the use of narcotic analgesics 
with the prevalence of constipation, and 3) assess the perceived impact 
of constipation on the well being and lifestyle of pediatric patients 
receiving chemotherapy. 
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Methods 
Participants were recruited from sites of the Yale Pediatric Oncology 
Program at Yale-New Haven Hospital and Pediatric 
Hematology/Oncology Associates in Guilford, CT.  We attempted to 
recruit all pediatric patients with cancer and on chemotherapy under 
age 21 when they presented at Yale-New Haven Hospital or the clinic in 
Guilford for chemotherapy infusions or office visits, and eligibility was 
determined by attending pediatric oncologists.  Recruitment continued 
until an average of zero new patients were being identified per clinic day.  
Patients and their families were not approached on a given day if any 
caregiver expressed any misgivings about whether the child was well 
enough for the discussion to be appropriate.  62 children were 
approached between June 2008 and February 2009, and only one 
patient/family member refused participation.  Approximately 75 new 
cases of cancer requiring chemotherapy were diagnosed each year at 
the time of recruitment, and we had an original goal of recruiting 75 
patients, however the rate of new patient recruitment became too slow 
after 61 were recruited.  All work regarding the gathering of data, 
including identifying potential participants, approaching patients and 
their families to explain the research and obtain consent/assent, 
interviewing patients/family members while administering the 
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questionnaire, and obtaining information from hospital/clinic charts, was 
performed by me. 
 The questionnaire was used first to collect demographic 
information, including name, date of birth, and medical record number to 
allow information to be gathered from the patient’s chart.  This 
information was later removed for data analysis.  Other demographic 
information included age, sex, weight, height, BMI, and clinic location.  
Patients or their parents were asked about cancer diagnosis, date of first 
cancer diagnosis, relapse information, current and past chemotherapy 
agents, history of pain medications, history of antiemetic medications, 
other medications, history of abdominal radiation, surgical history, and 
other medical history.  Patients were asked to qualify their activity level 
and oral intake as severely reduced, reduced, normal or high.  Any history 
of dehydration was noted.  Laxative use was explored in detail, including 
current laxatives with doses, previous laxative use during chemotherapy, 
whether laxative agents were changed and why, whether laxative use 
was prophylactic or as needed, and whether patients/parents thought 
that each laxative was effective.  The patient’s chart was reviewed for 
any additional information regarding the above parameters.  Specific 
information regarding bowel habits was obtained, and children and 
parents were asked about these parameters throughout the 
chemotherapy period to assess for constipation.  Constipation was 
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defined according to the North American Society of Pediatric 
Gastroenterology, Hepatology and Nutrition (NASPGHAN) criteria, defined 
as a delay or difficulty in defecation for 2 or more week and sufficient to 
cause significant distress to the patient (2,45).  History-based elements of 
the Rome III criteria for diagnosis of functional constipation were also 
obtained, specifically 2 or fewer bowel movements in the toilet per week, 
episodes of fecal incontinence in children > 4 years of age, history of 
retentive posturing or excessive volitional stool retention, history of painful 
or hard bowel movements,  history of large diameter stools which may 
obstruct the toilet, and duration of constipation (20).  Any perceived 
relationship of constipation to chemotherapy or other medications were 
also noted.  Patients/parents were also asked about formal diagnosis of 
constipation by a medical doctor, radiographic evidence of constipation, 
number of bowel movements per week, history of seeking physician care 
for constipation, longest period without a bowel movement after 
chemotherapy, and whether any constipation was worst at the beginning 
of chemotherapy.  Patients were asked about any history of diarrhea 
while on chemotherapy, and whether there was any relation of diarrhea 
to laxative use.  Any history of constipation prior to chemotherapy was 
noted, including any formal diagnosis by a physician, any baseline bowel 
movement frequency <3 per week, history of abdominal pain with bowel 
movements, episodes of fecal incontinence after age 4, history of 
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retentive posturing or excessive volitional stool retention, history of hard 
bowel movements, or previous laxative use.  Finally, the perceived impact 
of constipation was noted.  Children and parents were asked to qualify 
constipation on a scale of 0-3, with 0 indicating “not a problem,” 1 a 
“minor problem,” 2 a “significant problem,” or 3 a “major problem.”  They 
were also asked to rate the impact of constipation on their lifestyle also on 
a scale of 0-3, with 0 being “no impact,”  1 being “mild,” 2 being 
“significant,” or 3 being “severe impact.” 
 Statistical analysis of the association of various parameters with 
constipation was assessed using the Fisher exact test using a 2x2 
contingency table, with significance accepted at a P value of less than 
0.05.  These parameters included age group (<10 year, >10years), sex, 
obesity, abdominal radiation, previous history of constipation, or isolated 
or combined use of medications such as vincristine, methotrexate, 6-
mercaptopurine, cytosine arabinoside, and opiates.  Results of 
demographic data are presented as a mean and percent, while 
prevalence data is expressed as a percent ± the margin of error 
corresponding to a confidence interval of 95%. 
 This study was approved by the Human Investigation Committee of 
Yale University School of Medicine, HIC#0711003295.  I obtained informed 
consent from all parents of children less than 18 years of age and all 
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patients 18 years of age or older, and I obtained assent from all children 
ages 7 to 17. 
 
Results 
We were able to recruit sixty-one children to participate in this 
study.  Information regarding their demographic information, cancer 
diagnosis, chemotherapy agents received, and opiate use are included 
in Table 1.  No children were diagnosed with a gastrointestinal tract 
malignancy, and two children were subjected to abdominal radiation 
alongside their chemotherapy.  In addition to the chemotherapy agents 
listed, other chemotherapy agents included cyclophosphamide (n=13), 
doxorubicin (n=11), daunorubicin (n=6), bleomycin (n=6), etoposide (n=6), 
vinblastine (n=4), carboplatin (n=3), dacarbazine (n=3), temozolomide 
(n=2), actinomysin (n=2), gleomycin (n=2), and alpha-interferon (n=1).  
Besides chemotherapy, other commonly used medications included 
ondansetron (n=33), diphenhydramine (n=11), and acid suppression 
therapy (n=23) which included famotidine, ranitidine, and lansoprazole.  8 
children  
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TABLE 1.  Demographic Data
Patients 61
Mean age (y) 10.6
Age range (y) 1.1 to 20.4
Age < 10y 29 (48%)
Male 34 (55%)
Obese (BMI>95th percentile) 12 (20%)
Diagnosis:
Acute lymphoid leukemia 33 (54%)
Lymphomas 10 (16%)
Brain neoplasms 3 (5%)
Myeloid leukemia 3 (5%)
Other solid tumors 12 (20%)
Chemotherapy:
Vincristine 47 (77%)
Methotrexate 33 (54%)
6-mercaptopurine 28 (46%)
Cytosine arabinoside 12 (20%)
Mean chemotherapy duration (mo) 13
Chemotherapy duration range (mo) 1 to 48
Intermittent opiate use:
Any opiate 17 (28%)
Codeine 14 (23%)
Morphine 5 (8%)
Oxycodone 5 (8%)
Hydromorphone 2 (3%)  
underwent surgery for tumor resection, while 2 children had a history of 
inguinal hernia repair. 
Table 2 shows the bowel movement parameters recorded for 
children on chemotherapy for cancer.  35 of 61 children, or 57% ± 12% 
(margin of error corresponding to a 95% confidence interval [95% CI]) met 
NASPGHAN criteria for constipation by having delayed or difficult 
defecation for 2 weeks.  The mean duration of constipation was 2.4 wks, 
with a range of 2 to 6 weeks.  35 of 61 (57% ± 12% [95% CI]) children met 
two or more Rome III criteria for constipation, while 29 of 61 (48% ± 13% 
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[95% CI]) children (or their parents) reported that they had been 
diagnosed by a physician with constipation.  47 of 61 children (77% ± 11% 
[95% CI]) demonstrated some evidence of constipation, defined by any 
of the Rome III or NASPGHAN criteria.  46 of 61 (75% ± 11% [95% CI]) 
children (or their parents) reported that they had noticed a change in 
bowel habits they identified as constipation in the days immediately 
following receiving chemotherapy.  Of those who met NASPGHAN criteria 
for constipation, 33 patients or parents were asked if they noted the 
severity of constipation to be different early in the chemotherapy 
protocol.  27/33 (75% ± 11% [95% CI]) of these patients demonstrating 
constipation described the constipation as worst early in the protocol, 
such as during the induction phase.  15 of 61 (25% ± 11% [95% CI]) patients 
had at least one episode of diarrhea during chemotherapy. 
 
Association with Risk Factors, Medications, and Chemotherapy agents: 
The thirty-five children who satisfied the NASPGHAN criteria for 
constipation were assessed for risk factors for constipation and 
associations with medications and chemotherapy agents.  Seven of eight 
children (87.5% ± 23% [95% CI]) with a history of constipation before 
chemotherapy developed constipation while on chemotherapy.  No risk 
factors for constipation, including  
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TABLE 2.  Bowel Movement (BM) Parameters of Children on Cancer Chemotherapy
Percentage
(±95%CI)
NASPGHAN definition of constipation:
Delayed or difficult defecation for 2 wks 35/61 57% ± 12%
Rome III Criteria:
Painful or hard stools 46/61 75% ± 11%
Two or fewer defecations in the toilet per week 26/61 43% ± 12%
Large diameter stools which may obstruct the toilet 19/61 31% ± 12%
Retentive posturing or excessive volitional stool retention 10/61 16% ±  9%
>1 episode of fecal incontinence (in children > 4 years of age) 4/54 7.4% ± 7.0%
Rome III definition of constipation (without 2 month duration requirement):
2+ Rome III Criteria Met 35/61 57% ± 12%
X-Ray evidence of constipation 6/61 10% ±  7%
Physician diagnosis of constipation 29/61 48% ± 13%
Any above evidence suggestive of constipation 47/61 77% ± 11%
Association with receiving chemotherapy:
Constipation within days after receiving chemotherapy 46/61 75% ± 11%
Constipation noted to be worst early in chemotherapy protocol* 27/33 82% ± 13%
Longest duration after chemotherapy without a BM is at least 3d 23/61 38% ± 12%
Longest duration after chemotherapy without a BM is at least 7d 7/61  8% ±  8%
Diarrhea:
Episode of diarrhea while on chemotherapy 15/61 25% ± 11%
NASPGHAN indicates North American Society of Pediatric Gastroenterology, Hepatology, and Nutrition.
*Question asked of smaller subset of 25 patients with NASPGHAN constipation
NumbersBowel Movement Parameters
   
prior history of constipation as well as age group [either less than or 
greater than 10 years of age], sex, obesity, and abdominal radiation, 
reached statistical significance for association with constipation.  Amongst 
medications and chemotherapy agents, only combined use of vincristine 
and opiates was significantly associated with the development of 
constipation in children (p<0.03).  Isolated and combined use of other 
medications, including vincristine, methotrexate, 6-mercaptopurine, 
cytosine arabinoside, and opiates were also assessed for relation to 
constipation, however no other statistically significant associations were 
found. 
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Laxative Use 
 Table 3 shows the characterization of laxative use by children on 
chemotherapy.  42 of 61 children (69% ± 12% [95%CI]) on chemotherapy 
used a laxative at some point during their treatment regimen, and rates of 
individual laxatives are shown in table 3.  17 of 61 children (28% ± 11% [95% 
CI]) were placed on prophylactic laxative therapy.  Amongst these 42 
children, there were 60 different treatment regimens, with some children 
changing regimens over the course of their chemotherapy.  Of these 60 
regimens, 53 (88% ± 8% [95% CI]) were thought by patients or their parents 
to be effective, while 7 of 60 (12% ± 8% [95% CI]) had to be changed as 
they were thought to be ineffective.  While several of these ineffective 
regimens involved more than one agent, the involvement of the most 
common laxatives (polyethylene glycol [PEG] 3350, oral docusate, and 
senna glycosides) in these failed regimens is shown in table 3.   
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TABLE 3.  Laxative Use of Children on Cancer Chemotherapy
Percentage
(±95%CI)
Types of laxatives used:
Any laxative 42/61 69% ± 12%
Docusate (oral) 18/61 30% ± 11%
Senna glycosides 11/61 18% ± 10%
Polyethylene glycol (PEG) 3350 33/61 54% ± 13%
Effectiveness and failures of laxative therapy:
Laxative regimens thought to be ineffective* 7/60 12% ± 8%
Ineffective regimens which included docusate (oral) 4/7 57% ± 37%
Ineffective regimens which included senna glycosides 3/7 42% ± 37%
Ineffective regimens which included both docusate and senna 2/7 29% ± 33%
Ineffective regimens which included PEG 3350 1/7 14% ± 26%
Laxative users who eventually found an effective regimen 41/41 100% ± 0%
Laxative regimen tolerance:
Docusate (oral) regimens not tolerated (all discontinued) 1/18  6% ± 11%
Senna glycosides regimens not tolerated (all discontinued) 1/11 10% ± 17%
PEG 3350 regimens not tolerated (all discontinued) 2/33  6% ±  8%
*Some patients received multiple regimens
NumbersLaxative Use
 
The one ineffective regimen which included PEG 3350 was a regimen of a 
standing dose of oral docusate with PEG 3350 used on an as needed 
basis.  This was changed to a regimen of a standing dose of PEG 3350, 
which was effective.  Other regimens were discontinued due to failure of 
the patient to tolerate the laxative medication, due to either taste or the 
size of the medication pill.  These are also summarized in table 3.  Notably, 
8 children who used PEG 3350 as a laxative had diarrhea at some point 
during their chemotherapy, though in only 3 of 33 (9% ± 9% [95% CI]) PEG 
3350-containing regimens was the diarrhea temporally related to taking 
the PEG 3350. 
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Impact of constipation 
 Fourteen of thirty-five constipated children (40% ± 16% [95% CI]) 
sought the care of a medical doctor explicitly for constipation as their 
chief complaint during their course of chemotherapy, either in the office 
(9) or emergency room (3), and 2 were admitted for constipation after a 
visit for another reason.  When asked about the degree to which 
constipation was a problem on a 0 to 3 scale, 4 of 35 constipated children 
or their parents (11% ± 11% [95% CI]) stated that constipation was not a 
problem, 16 of 35 (46% ± 17% [95% CI]) stated that constipation was a 
minor problem, and 15 of 35 (43% ± 16% [95% CI]) stated that constipation 
was either a significant or a major problem.  This is summarized in figure 1.  
When asked about their perception of the degree to which constipation 
had impacted their lives on a 0 to 3 scale, 14 of 35 constipated children or 
their parents (40% ± 16% [95% CI]) stated that constipation had no  
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FIGURE 1.  Perception of the degree to which constipation is a problem 
among 35 children meeting NASPGHAN criteria for constipation, on a 
scale of 0 to 3.  (0=no problem, 1=minor, 2=significant, 3=major)
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FIGURE 2.  Perception of the impact of constipation on lifestyle among 35 
children meeting NASPGHAN criteria for constipation, on a scale of         
0 to 3.  (0=no impact, 1=minor, 2=significant, 3=major impact)
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Note: Error bars in all figures indicate the margin of error corresponding to a 95% 
confidence interval. 
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impact, 13 of 35 (37% ± 16% [95% CI]) stated that constipation had a minor 
impact, and 8 of 35 (23% ± 14% [95% CI]) stated that constipation had a 
significant or major impact on lifestyle.  These results are summarized in 
figure 2. 
 
Discussion 
 Of 61 children receiving chemotherapy for cancer enrolled in this 
study, 57% ± 12% (95% CI) were found to have experienced acute 
constipation, defined as delayed or difficult defecation for 2 weeks.  If the 
2 month time requirement of the Rome III criteria for functional 
constipation is set aside, the same prevalence is seen when this criteria is 
applied.  Both of these values are significantly higher than  estimations for 
constipation in the general pediatric population of 0.7% to 29.6%, p<0.05 
(16).  However, the sensitivity of both of these instruments is demonstrably 
low, given that 77% ± 11% (95% CI) had some signs and symptoms which 
are evidence of constipation including the onset of hard or painful stools, 
75% ± 11% (95% CI) noted self-described constipation within days of 
receiving chemotherapy, and 69% ± 12% (95% CI) required the use of a 
laxative regimen.  Defining constipation in children has been a devilishly 
difficult task, one which has required experts to frequently revise their 
widely used consensus expert opinions several times to address concerns 
about low sensitivity (16,46).  The issue with regards to the pediatric 
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oncology population is further complicated by the fact that >90% of 
cases of pediatric constipation in the literature are functional in nature, 
with no identifiable organic cause (16).  As functional constipation is a 
chronic condition, and as constipation’s signs and symptoms are so 
nonspecific (a 2011 study showed that 20% of 10 to 16-year-olds have at 
least 1 clinical feature of constipation [18]), expert consensus opinions 
such as the NASPGHAN or Rome III criteria have always attached a 
duration requirement to a combination of signs or symptoms in order both 
to increase specificity at the expense of sensitivity and to ensure that any 
changes in defecation are prolonged enough to warrant intervention.  
These concerns are ill-suited to a situation of acute iatrogenic 
constipation, as experienced by pediatric cancer patients.  As our results 
have shown, constipation in this population is experienced more as an 
acute reaction in the days immediately following receiving 
chemotherapy, especially during induction chemotherapy.  75% ± 11% 
(95% CI) of patients described a bout of constipation within days of 
chemotherapy, with 38% ± 12% (95% CI) going at least three days after 
chemotherapy infusion without a bowel movement (BM), and with 8% ± 
8% going a full 7 days or longer without a BM.  This level of constipation is 
not just very distressing to the patient but is also potentially dangerous, 
especially if fissures or abscesses develop in a neutropenic patient, risking 
systemic infection. 
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  No adequate or universally accepted criteria exist for the diagnosis 
of acute constipation in the pediatric oncologic population, and we are 
not aware of any definitions which have even been proposed.  It is clear, 
however, that current diagnostic algorithms are inadequate for this 
situation, and that this problem may be partially responsible for the lack of 
research into the effective management of constipation, which in turn 
may be contributing to undertreatment and the high prevalence of 
constipation in this community.  Based on the consistent stories of the 75% 
of children and parents who noted constipation within days after 
receiving chemotherapy, and based on the widely accepted existing 
Rome III and NASPGHAN criteria, I would thus propose that constipation in 
children on chemotherapy be defined as a deviation from baseline bowel 
habits in the days immediately following chemotherapy of any of the 
following: a delayed bowel movement defined as failing to have a BM 
within 24h of expected based on baseline BM frequency; difficulty with 
defecation such as straining, retentive posturing or excessive volitional 
stool retention; a painful or hard stool; or a large diameter stool which 
may obstruct the toilet.  As these changes come at a time when the 
pretest probability of constipation is very high (based on the results of this 
study), false positives would not be the problem that would likely be seen 
were these rules applied to the general population.  The temporal 
association of these bowel changes to chemotherapy, in addition to the 
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associated opiate use, antiemetic use, decreased oral intake, decreased 
activity level, poor hydration, and new psychological effects of 
chemotherapy infusions; strongly suggest that any changes to bowel 
habits are real and related to the jarring biological and psychological 
insult of chemotherapy. 
 The lack of a good definition for constipation certainly is a key 
piece of why so little information is known about the pervasiveness of the 
problem and how it should be addressed.  There are, however, other 
barriers as well.  Some authors have suggested that uncertainty regarding 
diagnosis conspires with a general lack of awareness or appreciation for 
the importance and scope of the issue (1,3).  Another problem is likely 
funding, as is evidenced by the large amount of quality information for 
more profitable medications for other common side effects of 
chemotherapy such as ondansetron and granisetron for nausea (36,39).  
As Phillips and Gibson point out in their review of constipation treatments 
for children receiving chemotherapy (which found no studies for 
inclusion), “it is difficult and expensive to set up, find sponsorship and data 
collection systems [sic] for a multicentre study” on therapeutic 
approaches to constipation for which treatments are relatively 
inexpensive (3).  They recommend including palliative care questions as 
two study arms tied into larger therapeutic trials, and this seems like a 
reasonable recommendation. 
 34 
 The diagnoses of our patients reflected the more common pediatric 
cancer diagnoses, and 90% of the patients recruited for our study had 
diagnoses of either acute lymphoid leukemia, non-CNS solid tumors, or 
lymphoma.  We assessed for several risk factors for constipation in our 
population.  For example, 12% ± 20% (95% CI) of our recruited patients 
were obese, which was recently shown to be a risk factor for constipation 
in children (47).  Obesity was not related to constipation in our study, 
though this study may not have been sufficiently powered to make this 
association should one exist.  The range of patient ages recruited for our 
study was broad (1.1y to 20.4y), although this means that fewer patients 
were gathered from each age group.  As 1-year-olds are certainly very 
different from 10-year-olds, who are in turn very different from 20-year-
olds, the lower power afforded by our sample size may not have been 
able to resolve any differences that might be seen amongst different age 
groups.   
This low power also restricted finding associations between 
constipation and certain suspect medications.  While the combination of 
vincristine and opiates was significantly associated with an increased risk 
of constipation (p<0.03) and likely has a particularly strong association, no 
other medication associations reached statistical significance in this study.  
This included isolated and combined use of vincristine, methotrexate, 6-
mercaptopurine, cytosine arabinoside, and opiates.  Vincristine affects 
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the gut through the induction of gastrointestinal neuropathy, which slows 
gastrointestinal motility.  Opiates have a similar effect by inhibiting mu 
receptors in the gastrointestinal nervous system, which inhibits peristalsis 
and also slows motility, and so the two medications may have a 
synergistic effect.  When a child is receiving both opiates and vincristine, 
providers must be especially vigilant for (or prophylax for) constipation. 
 The importance of addressing constipation is readily apparent in 
the data from this study.  While only 11% ± 11% (95% CI) of children with 
constipation by NASPGHAN criteria said that constipation was not a 
problem, 43% ± 16% (95% CI) identified it as a significant or major problem.  
This was in families dealing with the huge distracting problem of a life-
threatening cancer diagnosis in a child and all of the side effects of 
chemotherapy that entails.  That constipation was such a large problem 
to this group of people is very telling.  Indeed, in children functional 
constipation has been shown to negatively affect quality-of-life scores 
more than inflammatory bowel disease (48).  23% ± 11% (95% CI) also 
reported that constipation had either a significant or major effect on their 
lifestyle.  Beyond the patient experience, if a neutropenic child develops 
acute abdominal pain and abdominal distention from constipation, this 
can easily be confused with the presentation of neutropenic enterocolitis 
(2).  If constipation causes an anal fissure or abscess in a neutropenic 
patient, this can lead to systemic infection and even death.  Constipation 
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also was shown to contribute to healthcare costs in this group, with 14 
children seeking a physician’s care specifically for constipation, including 
9 in an outpatient setting, 3 in the emergency department, and 2 
admitted to the inpatient wards. 
 The adult literature treats constipation in patients on chemotherapy 
as a failure of prevention, and this may be a useful paradigm in the 
pediatric population as well (27).  Of note, every child we recruited who 
required the use of a laxative was able to find a regimen which was 
effective.  While our study was not designed or powered to evaluate or 
compare laxative regimens and is inadequate to reach definitive 
conclusions regarding therapy recommendations, interesting observations 
can be made.  Firstly, a wide range of management strategies, laxative 
agents, and dosages was used, demonstrating high variability in 
approaches to constipation.  This highlights the need to standardize 
treatments, both so that comparative studies can be carried out and 
because some physicians’ “strongly-held, beliefs driven and self-
introduced management strategies … [are] sometimes even harmful to 
children” (46).  60 individual laxative regimens were used in 42 of 61 (69% ± 
12% [95% CI]) children (some children used different successive regimens), 
with PEG 3350 being the most common component (54% ± 13% [95% CI]) 
followed by oral docusate (30% ± 11% [95% CI]) and senna glycosides 
(18% ± 10% [95% CI]).  Of these regimens, 4 were not tolerated due to 
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taste or the size of the pills involved (two PEG 3350 regimens due to taste, 
one oral docusate regimen due to pill size and one senna glycosides 
regimen for an unknown reason).  7 regimens were discontinued as they 
were ineffective at controlling constipation.  Interestingly, while four of 
these regimens included oral docusate and three involved senna 
glycosides (all of which were changed to PEG 3350 which was 
subsequently effective), the only PEG 3350-containing regimen which was 
ineffective was a regimen consisting of a standing dose of oral docusate 
with PEG 3350 taken as needed.  This regimen was switched to daily PEG 
3350, which was effective, and thus there were actually no treatment 
failures beyond intolerance to taste in 2 of 33 cases (6% ± 8% [95% CI]) 
observed with PEG 3350.  PEG 3350 may therefore be a promising 
candidate for prophylactic treatments or standardized regimens.  Based 
on current guidelines for the treatment of functional constipation in 
children, I would recommend either prophylactic PEG 3350 0.26-
0.84g/kg/day starting the day of chemotherapy or a stepwise protocol of 
daily dose increases starting from 0.26-0.84g/kg/day (maintenance dose) 
increasing to 1-1.5 g/kg/day (disimpaction dose) for a missed bowel 
movement after chemotherapy (46). 
 There are several important limitations to this study.  In addition to 
the low power afforded by the relatively low sample size we were 
practically able to recruit, this survey study is susceptible to recall bias, 
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where knowing the study is about constipation on chemotherapy may 
lead to either an increase or decrease in the observed prevalence of 
constipation if false associations of constipation memories with 
chemotherapy are made or if patients have forgotten episodes of 
constipation.  Response bias, where patients deliberately conceal 
episodes of constipation for reasons of embarrassment or invent episodes 
to please the interviewer, is also a possibility which would increase or 
decrease the observed rates of constipation, respectively.  Furthermore, 
the temporal associations between episodes of chemotherapy and 
constipation may be the result of physicians’ warnings of the side effects 
of treatment.  Regarding self-reported perceptions of the degree to which 
constipation was a problem or impacted one’s lifestyle, it is possible that 
children and parents associated the stress and side effects of 
chemotherapy with any episodes of constipation, inflating the impact 
attributed to constipation (2).   
 In conclusion, the study’s principle goal was achieved, supporting 
the hypothesis that the prevalence in constipation in children receiving 
chemotherapy was high, observed at 57% ± 12% (95% CI) using the 
NASPGHAN criteria for constipation, though the actual prevalence may 
be higher.  This prevalence is certainly higher than previous estimates for 
the general pediatric population.  Constipation is significantly associated 
with the combination of vincristine and opiates (p<0.03), even in this study 
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of limited power.  Furthermore, this constipation is seen as either a 
significant or major problem in 43% ± 16% of cases, with a significant or 
major impact on lifestyle in 23% ± 14% of cases.  It is a side effect which 
requires greater attention, standardization of treatment, and further 
research into comparative laxative effectiveness in order to address this 
important condition. 
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